Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups

Our aim was to investigate whether molecular classification can be used to refine prognosis in grade 3 endometrial endometrioid carcinomas (EECs). Grade 3 EECs were classified into 4 subgroups: p53 abnormal, based on mutant-like immunostaining (p53abn); MMR deficient, based on loss of mismatch repai...

ver descrição completa

Detalhes bibliográficos
Autores: Bosse, Tjalling, Nout, Remi A., McAlpine, Jessica N., McConechy, Melissa K., Britton, Heidi, Hussein, Yaser, Gonzalez, Carlene, Ganesan, Raji, Steele, Jane C., Harrison, Beth T., Oliva, Esther, Vidal-Bel, August, Matias-Guiu, Xavier, 1958-, Abu-Rustum, Nadeem R., Levine, Douglas A., Gilks, C. Blake, Soslow, Robert A.
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2018
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/172821
Acesso em linha:https://hdl.handle.net/2445/172821
Access Level:acceso abierto
Palavra-chave:Càncer d'endometri
Pronòstic mèdic
Endometrial cancer
Prognosis
id ES_c4eeceee23bd1260c09fdb9ff13fce6c
oai_identifier_str oai:recercat.cat:2445/172821
network_acronym_str ES
network_name_str España
repository_id_str
spelling Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic SubgroupsBosse, TjallingNout, Remi A.McAlpine, Jessica N.McConechy, Melissa K.Britton, HeidiHussein, YaserGonzalez, CarleneGanesan, RajiSteele, Jane C.Harrison, Beth T.Oliva, EstherVidal-Bel, AugustMatias-Guiu, Xavier, 1958-Abu-Rustum, Nadeem R.Levine, Douglas A.Gilks, C. BlakeSoslow, Robert A.Càncer d'endometriPronòstic mèdicEndometrial cancerPrognosisOur aim was to investigate whether molecular classification can be used to refine prognosis in grade 3 endometrial endometrioid carcinomas (EECs). Grade 3 EECs were classified into 4 subgroups: p53 abnormal, based on mutant-like immunostaining (p53abn); MMR deficient, based on loss of mismatch repair protein expression (MMRd); presence of POLE exonuclease domain hotspot mutation (POLE); no specific molecular profile (NSMP), in which none of these aberrations were present. Overall survival (OS) and recurrence-free survival (RFS) rates were compared using the Kaplan-Meier method (Log-rank test) and univariable and multivariable Cox proportional hazard models. In total, 381 patients were included. The median age was 66 years (range, 33 to 96 y). Federation Internationale de Gynecologie et d'Obstetrique stages (2009) were as follows: IA, 171 (44.9%); IB, 120 (31.5%); II, 24 (6.3%); III, 50 (13.1%); IV, 11 (2.9%). There were 49 (12.9%) POLE, 79 (20.7%) p53abn, 115 (30.2%) NSMP, and 138 (36.2%) MMRd tumors. Median follow-up of patients was 6.1 years (range, 0.2 to 17.0 y). Compared to patients with NSMP, patients with POLE mutant grade 3 EEC (OS: hazard ratio [HR], 0.36 [95% confidence interval, 0.18-0.70]; P=0.003; RFS: HR, 0.17 [0.05-0.54]; P=0.003) had a significantly better prognosis; patients with p53abn tumors had a significantly worse RFS (HR, 1.73 [1.09-2.74]; P=0.021); patients with MMRd tumors showed a trend toward better RFS. Estimated 5-year OS rates were as follows: POLE 89%, MMRd 75%, NSMP 69%, p53abn 55% (Log rank P=0.001). Five-year RFS rates were as follows: POLE 96%, MMRd 77%, NSMP 64%, p53abn 47% (P=0.000001), respectively. In a multivariable Cox model that included age and Federation Internationale de Gynecologie et d'Obstetrique stage, POLE and MMRd status remained independent prognostic factors for better RFS; p53 status was an independent prognostic factor for worse RFS. Molecular classification of grade 3 EECs reveals that these tumors are a mixture of molecular subtypes of endometrial carcinoma, rather than a homogeneous group. The addition of molecular markers identifies prognostic subgroups, with potential therapeutic implications.Wolters Kluwer Health2020202020182020info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion8 p.application/pdfhttps://hdl.handle.net/2445/172821Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1097/PAS.0000000000001020American Journal of Surgical Pathology, 2018, vol. 42, num. 5, p. 561-568https://doi.org/10.1097/PAS.0000000000001020(c) Wolters Kluwer Health, 2018info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1728212026-05-29T05:05:01Z
dc.title.none.fl_str_mv Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
title Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
spellingShingle Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
Bosse, Tjalling
Càncer d'endometri
Pronòstic mèdic
Endometrial cancer
Prognosis
title_short Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
title_full Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
title_fullStr Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
title_full_unstemmed Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
title_sort Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
dc.creator.none.fl_str_mv Bosse, Tjalling
Nout, Remi A.
McAlpine, Jessica N.
McConechy, Melissa K.
Britton, Heidi
Hussein, Yaser
Gonzalez, Carlene
Ganesan, Raji
Steele, Jane C.
Harrison, Beth T.
Oliva, Esther
Vidal-Bel, August
Matias-Guiu, Xavier, 1958-
Abu-Rustum, Nadeem R.
Levine, Douglas A.
Gilks, C. Blake
Soslow, Robert A.
author Bosse, Tjalling
author_facet Bosse, Tjalling
Nout, Remi A.
McAlpine, Jessica N.
McConechy, Melissa K.
Britton, Heidi
Hussein, Yaser
Gonzalez, Carlene
Ganesan, Raji
Steele, Jane C.
Harrison, Beth T.
Oliva, Esther
Vidal-Bel, August
Matias-Guiu, Xavier, 1958-
Abu-Rustum, Nadeem R.
Levine, Douglas A.
Gilks, C. Blake
Soslow, Robert A.
author_role author
author2 Nout, Remi A.
McAlpine, Jessica N.
McConechy, Melissa K.
Britton, Heidi
Hussein, Yaser
Gonzalez, Carlene
Ganesan, Raji
Steele, Jane C.
Harrison, Beth T.
Oliva, Esther
Vidal-Bel, August
Matias-Guiu, Xavier, 1958-
Abu-Rustum, Nadeem R.
Levine, Douglas A.
Gilks, C. Blake
Soslow, Robert A.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Càncer d'endometri
Pronòstic mèdic
Endometrial cancer
Prognosis
topic Càncer d'endometri
Pronòstic mèdic
Endometrial cancer
Prognosis
description Our aim was to investigate whether molecular classification can be used to refine prognosis in grade 3 endometrial endometrioid carcinomas (EECs). Grade 3 EECs were classified into 4 subgroups: p53 abnormal, based on mutant-like immunostaining (p53abn); MMR deficient, based on loss of mismatch repair protein expression (MMRd); presence of POLE exonuclease domain hotspot mutation (POLE); no specific molecular profile (NSMP), in which none of these aberrations were present. Overall survival (OS) and recurrence-free survival (RFS) rates were compared using the Kaplan-Meier method (Log-rank test) and univariable and multivariable Cox proportional hazard models. In total, 381 patients were included. The median age was 66 years (range, 33 to 96 y). Federation Internationale de Gynecologie et d'Obstetrique stages (2009) were as follows: IA, 171 (44.9%); IB, 120 (31.5%); II, 24 (6.3%); III, 50 (13.1%); IV, 11 (2.9%). There were 49 (12.9%) POLE, 79 (20.7%) p53abn, 115 (30.2%) NSMP, and 138 (36.2%) MMRd tumors. Median follow-up of patients was 6.1 years (range, 0.2 to 17.0 y). Compared to patients with NSMP, patients with POLE mutant grade 3 EEC (OS: hazard ratio [HR], 0.36 [95% confidence interval, 0.18-0.70]; P=0.003; RFS: HR, 0.17 [0.05-0.54]; P=0.003) had a significantly better prognosis; patients with p53abn tumors had a significantly worse RFS (HR, 1.73 [1.09-2.74]; P=0.021); patients with MMRd tumors showed a trend toward better RFS. Estimated 5-year OS rates were as follows: POLE 89%, MMRd 75%, NSMP 69%, p53abn 55% (Log rank P=0.001). Five-year RFS rates were as follows: POLE 96%, MMRd 77%, NSMP 64%, p53abn 47% (P=0.000001), respectively. In a multivariable Cox model that included age and Federation Internationale de Gynecologie et d'Obstetrique stage, POLE and MMRd status remained independent prognostic factors for better RFS; p53 status was an independent prognostic factor for worse RFS. Molecular classification of grade 3 EECs reveals that these tumors are a mixture of molecular subtypes of endometrial carcinoma, rather than a homogeneous group. The addition of molecular markers identifies prognostic subgroups, with potential therapeutic implications.
publishDate 2018
dc.date.none.fl_str_mv 2018
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/172821
url https://hdl.handle.net/2445/172821
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1097/PAS.0000000000001020
American Journal of Surgical Pathology, 2018, vol. 42, num. 5, p. 561-568
https://doi.org/10.1097/PAS.0000000000001020
dc.rights.none.fl_str_mv (c) Wolters Kluwer Health, 2018
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Wolters Kluwer Health, 2018
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 8 p.
application/pdf
dc.publisher.none.fl_str_mv Wolters Kluwer Health
publisher.none.fl_str_mv Wolters Kluwer Health
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418945039040512
score 15,81155

Registos relacionados